United States Hypereosinophilic Syndrome Drug Market Report 2017

December 2017 | 96 pages | ID: U2B49FE6524EN
QYResearch

Abstracts

In this report, the United States Hypereosinophilic Syndrome Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Hypereosinophilic Syndrome Drug in these regions, from 2012 to 2022 (forecast).

United States Hypereosinophilic Syndrome Drug market competition by top manufacturers/players, with Hypereosinophilic Syndrome Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Bristol-Myers Squibb Co
• GlaxoSmithKline Plc
• Knopp Biosciences LLC
• Kyowa Hakko Kirin Co Ltd
• Stemline Therapeutics Inc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Benralizumab
• Dasatinib
• Dexpramipexole Dihydrochloride
• Mepolizumab
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Research Center
• Hospital
• Clinic

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Hypereosinophilic Syndrome Drug Market Report 2017

1 HYPEREOSINOPHILIC SYNDROME DRUG OVERVIEW

1.1 Product Overview and Scope of Hypereosinophilic Syndrome Drug
1.2 Classification of Hypereosinophilic Syndrome Drug by Product Category
  1.2.1 United States Hypereosinophilic Syndrome Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Hypereosinophilic Syndrome Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Benralizumab
  1.2.4 Dasatinib
  1.2.5 Dexpramipexole Dihydrochloride
  1.2.6 Mepolizumab
  1.2.7 Others
1.3 United States Hypereosinophilic Syndrome Drug Market by Application/End Users
  1.3.1 United States Hypereosinophilic Syndrome Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Research Center
  1.3.3 Hospital
  1.3.4 Clinic
1.4 United States Hypereosinophilic Syndrome Drug Market by Region
  1.4.1 United States Hypereosinophilic Syndrome Drug Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Hypereosinophilic Syndrome Drug Status and Prospect (2012-2022)
  1.4.3 Southwest Hypereosinophilic Syndrome Drug Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Hypereosinophilic Syndrome Drug Status and Prospect (2012-2022)
  1.4.5 New England Hypereosinophilic Syndrome Drug Status and Prospect (2012-2022)
  1.4.6 The South Hypereosinophilic Syndrome Drug Status and Prospect (2012-2022)
  1.4.7 The Midwest Hypereosinophilic Syndrome Drug Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Hypereosinophilic Syndrome Drug (2012-2022)
  1.5.1 United States Hypereosinophilic Syndrome Drug Sales and Growth Rate (2012-2022)
  1.5.2 United States Hypereosinophilic Syndrome Drug Revenue and Growth Rate (2012-2022)

2 UNITED STATES HYPEREOSINOPHILIC SYNDROME DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Hypereosinophilic Syndrome Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Hypereosinophilic Syndrome Drug Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Hypereosinophilic Syndrome Drug Average Price by Players/Suppliers (2012-2017)
2.4 United States Hypereosinophilic Syndrome Drug Market Competitive Situation and Trends
  2.4.1 United States Hypereosinophilic Syndrome Drug Market Concentration Rate
  2.4.2 United States Hypereosinophilic Syndrome Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Hypereosinophilic Syndrome Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES HYPEREOSINOPHILIC SYNDROME DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Hypereosinophilic Syndrome Drug Sales and Market Share by Region (2012-2017)
3.2 United States Hypereosinophilic Syndrome Drug Revenue and Market Share by Region (2012-2017)
3.3 United States Hypereosinophilic Syndrome Drug Price by Region (2012-2017)

4 UNITED STATES HYPEREOSINOPHILIC SYNDROME DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Hypereosinophilic Syndrome Drug Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Hypereosinophilic Syndrome Drug Revenue and Market Share by Type (2012-2017)
4.3 United States Hypereosinophilic Syndrome Drug Price by Type (2012-2017)
4.4 United States Hypereosinophilic Syndrome Drug Sales Growth Rate by Type (2012-2017)

5 UNITED STATES HYPEREOSINOPHILIC SYNDROME DRUG SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Hypereosinophilic Syndrome Drug Sales and Market Share by Application (2012-2017)
5.2 United States Hypereosinophilic Syndrome Drug Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES HYPEREOSINOPHILIC SYNDROME DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Bristol-Myers Squibb Co
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Hypereosinophilic Syndrome Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 GlaxoSmithKline Plc
  6.2.2 Hypereosinophilic Syndrome Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Knopp Biosciences LLC
  6.3.2 Hypereosinophilic Syndrome Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Kyowa Hakko Kirin Co Ltd
  6.4.2 Hypereosinophilic Syndrome Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Stemline Therapeutics Inc
  6.5.2 Hypereosinophilic Syndrome Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview

7 HYPEREOSINOPHILIC SYNDROME DRUG MANUFACTURING COST ANALYSIS

7.1 Hypereosinophilic Syndrome Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Hypereosinophilic Syndrome Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Hypereosinophilic Syndrome Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Hypereosinophilic Syndrome Drug Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Hypereosinophilic Syndrome Drug Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Hypereosinophilic Syndrome Drug Sales Volume Forecast by Type (2017-2022)
11.3 United States Hypereosinophilic Syndrome Drug Sales Volume Forecast by Application (2017-2022)
11.4 United States Hypereosinophilic Syndrome Drug Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Hypereosinophilic Syndrome Drug
Figure United States Hypereosinophilic Syndrome Drug Market Size (K Pcs) by Type (2012-2022)
Figure United States Hypereosinophilic Syndrome Drug Sales Volume Market Share by Type (Product Category) in 2016
Figure Benralizumab Product Picture
Figure Dasatinib Product Picture
Figure Dexpramipexole Dihydrochloride Product Picture
Figure Mepolizumab Product Picture
Figure Others Product Picture
Figure United States Hypereosinophilic Syndrome Drug Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Hypereosinophilic Syndrome Drug by Application in 2016
Figure Research Center Examples
Table Key Downstream Customer in Research Center
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure United States Hypereosinophilic Syndrome Drug Market Size (Million USD) by Region (2012-2022)
Figure The West Hypereosinophilic Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Hypereosinophilic Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Hypereosinophilic Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Hypereosinophilic Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Hypereosinophilic Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Hypereosinophilic Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Hypereosinophilic Syndrome Drug Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Hypereosinophilic Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Hypereosinophilic Syndrome Drug Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Hypereosinophilic Syndrome Drug Sales Share by Players/Suppliers
Figure 2017 United States Hypereosinophilic Syndrome Drug Sales Share by Players/Suppliers
Figure United States Hypereosinophilic Syndrome Drug Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Hypereosinophilic Syndrome Drug Revenue Share by Players/Suppliers
Figure 2017 United States Hypereosinophilic Syndrome Drug Revenue Share by Players/Suppliers
Table United States Market Hypereosinophilic Syndrome Drug Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Hypereosinophilic Syndrome Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Hypereosinophilic Syndrome Drug Market Share of Top 3 Players/Suppliers
Figure United States Hypereosinophilic Syndrome Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Hypereosinophilic Syndrome Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Hypereosinophilic Syndrome Drug Product Category
Table United States Hypereosinophilic Syndrome Drug Sales (K Pcs) by Region (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Sales Share by Region (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Sales Share by Region (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Sales Market Share by Region in 2016
Table United States Hypereosinophilic Syndrome Drug Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Revenue Share by Region (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Revenue Market Share by Region (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Revenue Market Share by Region in 2016
Table United States Hypereosinophilic Syndrome Drug Price (USD/Pcs) by Region (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Sales (K Pcs) by Type (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Sales Share by Type (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Sales Share by Type (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Sales Market Share by Type in 2016
Table United States Hypereosinophilic Syndrome Drug Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Hypereosinophilic Syndrome Drug by Type (2012-2017)
Figure Revenue Market Share of Hypereosinophilic Syndrome Drug by Type in 2016
Table United States Hypereosinophilic Syndrome Drug Price (USD/Pcs) by Types (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Sales Growth Rate by Type (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Sales (K Pcs) by Application (2012-2017)
Table United States Hypereosinophilic Syndrome Drug Sales Market Share by Application (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Sales Market Share by Application (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Sales Market Share by Application in 2016
Table United States Hypereosinophilic Syndrome Drug Sales Growth Rate by Application (2012-2017)
Figure United States Hypereosinophilic Syndrome Drug Sales Growth Rate by Application (2012-2017)
Table Bristol-Myers Squibb Co Basic Information List
Table Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Revenue Market Share in United States (2012-2017)
Table GlaxoSmithKline Plc Basic Information List
Table GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales Growth Rate (2012-2017)
Figure GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales Market Share in United States (2012-2017)
Figure GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Revenue Market Share in United States (2012-2017)
Table Knopp Biosciences LLC Basic Information List
Table Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales Growth Rate (2012-2017)
Figure Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales Market Share in United States (2012-2017)
Figure Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Revenue Market Share in United States (2012-2017)
Table Kyowa Hakko Kirin Co Ltd Basic Information List
Table Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales Growth Rate (2012-2017)
Figure Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales Market Share in United States (2012-2017)
Figure Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Revenue Market Share in United States (2012-2017)
Table Stemline Therapeutics Inc Basic Information List
Table Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales Growth Rate (2012-2017)
Figure Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales Market Share in United States (2012-2017)
Figure Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Hypereosinophilic Syndrome Drug
Figure Manufacturing Process Analysis of Hypereosinophilic Syndrome Drug
Figure Hypereosinophilic Syndrome Drug Industrial Chain Analysis
Table Raw Materials Sources of Hypereosinophilic Syndrome Drug Major Players/Suppliers in 2016
Table Major Buyers of Hypereosinophilic Syndrome Drug
Table Distributors/Traders List
Figure United States Hypereosinophilic Syndrome Drug Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Hypereosinophilic Syndrome Drug Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Hypereosinophilic Syndrome Drug Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Hypereosinophilic Syndrome Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Hypereosinophilic Syndrome Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Hypereosinophilic Syndrome Drug Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Hypereosinophilic Syndrome Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Hypereosinophilic Syndrome Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Hypereosinophilic Syndrome Drug Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Hypereosinophilic Syndrome Drug Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Hypereosinophilic Syndrome Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Hypereosinophilic Syndrome Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Hypereosinophilic Syndrome Drug Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources